Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of rifaximin in patients with postoperative Crohn's disease

Trial Profile

A clinical study of rifaximin in patients with postoperative Crohn's disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2018 New trial record
    • 29 Oct 2018 According to a Salix Pharmaceuticals media release, Salix Pharmaceuticals and Alfasigma has entered into agreement to initiate the late stage clinical program to study rifaximin in patients with postoperative Crohn's disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top